MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Boehringer Ingelheim.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Pulmonology · Pulmonary Fibrosis
- Sub-indication
- Ild
Related signal: Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients